Currently, the common biomarkers for NPC diagnosis and prognosis are mainly EBV antibodies (such as VCA‐IgA, EA‐IgA, and Zta‐IgG) and circulating EBV DNA copy number (Liu et al, 2012; Kim et al, 2017). This evidence concerns the gene CD79A and nasopharyngeal carcinoma.